| |
Unadjusted
|
Adjusted
|
|---|
| |
Beta
|
P
|
95% CI
|
Beta
|
P
|
95% CI
|
|---|
|
Female gender
|
0.492
|
0.011
|
0.118 to 0.865
|
0.621
|
0.004
|
0.220 to 1.022
|
|
Age
|
–0.004
|
0.669
|
–0.024 to 0.016
|
–0.001
|
0.919
|
–0.021 to 0.019
|
|
Anti-TNF ± MTX
|
–0.505
|
0.008
|
–0.866 to –0.143
|
–0.448
|
0.032
|
–0.855 to –0.041
|
|
RDD
|
–0.026
|
0.033
|
–0.049 to –0.002
|
–0.024
|
0.068
|
–0.050 to 0.002
|
|
PsA
|
–0.067
|
0.779
|
–0.550 to 0.416
|
0.064
|
0.733
|
–0.386 to 0.514
|
|
AS
|
–0.267
|
0.242
|
–0.722 to 0.188
|
0.219
|
0.419
|
–0.327 to 0.765
|
|
CRP
|
–0.004
|
0.523
|
–0.017 to 0.009
| | | |
|
ESR
|
–0.002
|
0.771
|
–0.017 to 0.013
| | | |
|
PTX3
|
–0.071
|
0.255
|
–0.194 to 0.053
| | | |
|
PGA
|
0.008
|
0.160
|
–0.003 to 0.019
| | | |
|
PtGA
|
–0.001
|
0.824
|
–0.008 to 0.006
| | | |
|
MHAQ
|
–0.328
|
0.332
|
–1.006 to 0.349
| | | |
|
NSJ
|
–0.150
|
0.050
|
–0.299 to 0.000
| | | |
- Comparators: female gender versus male gender, anti-TNF ± MTX versus MTX monotherapy
- Statistically significant differences are shown in bold typeface
-
anti-TNF anti-tumor necrosis factor, AS ankylosing spondylitis, CI confidence interval, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MHAQ Medical Health Assessment Questionnaire, MTX methotrexate, NSJ number of swollen joints, PGA Physicians' Global Assessment Score of Disease Activity, PsA psoriatic arthritis, PtGA Patients' Global Assessment Score of Disease Activity, PTX3 pentraxin 3, RDD rheumatic disease duration, RHI Reactive Hyperemic Index
